Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series.

Cancer reports (Hoboken, N.J.)·2026

Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026

Same author

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A <i>DPYD</i> Variant Allele.

JCO precision oncology·2026

Same author

High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities.

Nature communications·2026

Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026

Same author

[<sup>89</sup>Zr]bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic <i>NF2</i>-related schwannomatosis: a study protocol for a phase II single centre, prospective, feasibility trial.

BMJ open·2026

Search research articles

Related Experiment Video

Updated: May 15, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Neovascular prostate specific membrane antigen (PSMA) expression in bone and soft tissue sarcoma: a systematic

Irene A Spiridon^1,2, Sheena L M Ong¹, Jiri Soukup^1,3,4

¹Department of Pathology, Leiden University Medical Center, Postzone L1-Q, Postbus 9600, 2300 RC, Leiden, The Netherlands.

Virchows Archiv : an International Journal of Pathology

|April 8, 2025

Summary

Prostate-specific membrane antigen (PSMA) is expressed in a subset of bone and soft tissue tumors. This finding suggests potential benefits from PSMA-targeted imaging and radioligand therapy for these rare cancers.

Keywords:

Angiosarcoma Bone tumors Giant cell tumor of bone Hemangioma Immunohistochemistry Osteosarcoma PSMA Soft tissue sarcoma

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Related Experiment Videos

Last Updated: May 15, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Area of Science:

Oncology
Molecular Imaging
Cancer Biology

Background:

Bone and soft tissue sarcomas are rare, heterogeneous mesenchymal cancers with limited treatment options beyond surgery.
Prostate-specific membrane antigen (PSMA) is a promising target for radioligand therapy, particularly in prostate cancer.
Previous studies suggest PSMA expression in the neovasculature of soft tissue sarcomas and incidental uptake in hemangiomas.

Purpose of the Study:

To systematically investigate prostate-specific membrane antigen (PSMA) expression in a wide range of bone and soft tissue tumors.
To confirm and expand upon previous findings of PSMA expression in soft tissue sarcomas.
To evaluate the potential of PSMA-targeted therapies for bone and soft tissue sarcomas.

Main Methods:

Immunohistochemistry was employed to assess PSMA expression.
A cohort of 706 diverse tumor samples, including bone sarcomas, soft tissue sarcomas, and vascular tumors, were analyzed.
Tumor samples were scored for PSMA expression, with a focus on neovascular and tumor cell expression.

Main Results:

High PSMA expression in tumor neovasculature was observed in 29% of soft tissue sarcomas and 33% of bone sarcomas.
Malignant bone and soft tissue tumors, including rhabdomyosarcoma, mesenchymal chondrosarcoma, undifferentiated sarcoma, and osteosarcoma, frequently expressed PSMA.
Giant cell tumor of bone also showed high PSMA labeling in 67% of cases. Non-neoplastic vessels in vascular tumors exhibited lower PSMA expression (0-40%).

Conclusions:

A significant subset of bone and soft tissue tumors, encompassing both malignant and intermediate-grade types, express prostate-specific membrane antigen (PSMA).
These findings support the potential utility of PSMA-targeted positron emission tomography/computed tomography (PET/CT) scans for diagnosis and staging.
Patients with PSMA-expressing bone and soft tissue tumors may be candidates for novel PSMA-targeted radioligand therapies.